Twist Bioscience Corporation (TWST) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.88B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-655.00K; Retained Earnings (Accumulated Deficit)USD $-1.43B.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.85B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-639.00K; Retained Earnings (Accumulated Deficit)USD $-1.39B.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.81B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-571.00K; Retained Earnings (Accumulated Deficit)USD $-1.35B.
- 2025-09-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $1.79B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-627.00K; Retained Earnings (Accumulated Deficit)USD $-1.32B.
Twist Bioscience Corporation Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $1.88B | $-655.00K | $-1.43B | $445.74M | (m) | 3 month · $18.18M 9 month · $50.41M | (m) | (m) |
| 2026-03-31 | $1.00K | $1.85B | $-639.00K | $-1.39B | $455.09M | (m) | 3 month · $18.95M 6 month · $32.24M | (m) | (m) |
| 2025-12-31 | $0.00 | $1.81B | $-571.00K | $-1.35B | $456.10M | (m) | 3 month · $13.29M | (m) | (m) |
| 2025-09-30 | $0.00 | $1.79B | $-627.00K | $-1.32B | $472.96M | (m) | 12 month · $64.50M | (m) | (m) |
| 2025-06-30 | $0.00 | $1.77B | $-864.00K | $-1.29B | $478.20M | (m) | 3 month · $16.08M 9 month · $48.42M | (m) | (m) |
| 2025-03-31 | $0.00 | $1.75B | $-662.00K | $-1.31B | $440.11M | (m) | 3 month · $20.31M 6 month · $32.34M | (m) | (m) |
| 2024-12-31 | $0.00 | $1.73B | $-649.00K | $-1.27B | $455.94M | (m) | 3 month · $12.03M | (m) | (m) |
| 2024-09-30 | $0.00 | $1.72B | $-522.00K | $-1.24B | $472.69M | (m) | 12 month · $51.01M | (m) | (m) |
| 2024-06-30 | $0.00 | $1.70B | $-735.00K | $-1.21B | $491.14M | (m) | 3 month · $13.75M 9 month · $38.64M | (m) | (m) |
| 2024-03-31 | $0.00 | $1.68B | $-660.00K | $-1.12B | $560.13M | (m) | 3 month · $13.85M 6 month · $24.90M | (m) | (m) |
| 2023-12-31 | $0.00 | $1.67B | $-565.00K | $-1.08B | $590.04M | (m) | 3 month · $11.05M | (m) | (m) |
| 2023-09-30 | $0.00 | $1.66B | $-756.00K | $-1.03B | $623.43M | (m) | 12 month · $30.82M | (m) | (m) |
| 2023-06-30 | $0.00 | $1.64B | $-635.00K | $-986.79M | $657.55M | (m) | 3 month · $10.66M 9 month · $19.02M | (m) | (m) |
| 2023-03-31 | $0.00 | $1.63B | $111.00K | $-929.40M | $703.93M | (m) | 3 month · $10.43M 6 month · $8.35M | (m) | (m) |
| 2022-12-31 | $0.00 | $1.62B | $-609.00K | $-870.24M | $746.33M | (m) | 3 month · $-2.07M | (m) | (m) |
| 2022-09-30 | $0.00 | $1.62B | $-1.84M | $-828.42M | $789.38M | 12 month · $17.68M | 12 month · $79.66M | (m) | (m) |
| 2022-06-30 | $0.00 | $1.60B | $-1.38M | $-777.30M | $820.68M | 3 month · $17.68M 9 month · $17.68M | 3 month · $20.04M 9 month · $60.62M | (m) | (m) |
| 2022-03-31 | $0.00 | $1.58B | $-475.00K | $-716.78M | $863.36M | 3 month · $17.68M 6 month · $17.68M | 3 month · $22.46M 6 month · $40.57M | (m) | (m) |
| 2021-12-31 | (m) | $1.28B | $363.00K | $-656.12M | $626.18M | (m) | 3 month · $18.11M | (m) | (m) |
| 2021-09-30 | $0.00 | $1.19B | $546.00K | $-610.55M | $580.82M | 12 month · $21.14M | 12 month · $37.00M | (m) | (m) |
| 2021-06-30 | (m) | $1.18B | $428.00K | $-569.31M | $610.45M | 9 month · $21.14M | 3 month · $9.18M 9 month · $27.75M | (m) | (m) |
| 2021-03-31 | (m) | $1.14B | $190.00K | $-529.27M | $614.18M | 6 month · $21.11M | 3 month · $11.55M 6 month · $18.57M | (m) | (m) |
| 2020-12-31 | (m) | $1.13B | $142.00K | $-491.36M | $637.95M | (m) | 3 month · $7.02M | (m) | (m) |
| 2020-09-30 | $0.00 | $794.63M | $87.00K | $-458.45M | $336.26M | 12 month · $18.92M | 12 month · $17.10M | (m) | (m) |
| 2020-06-30 | (m) | $782.95M | $134.00K | $-434.14M | $348.95M | (m) | 3 month · $4.07M 9 month · $11.96M | (m) | (m) |
| 2020-03-31 | (m) | $669.92M | $213.00K | $-405.93M | $264.20M | (m) | 3 month · $4.20M 6 month · $7.89M | (m) | (m) |
| 2019-12-31 | (m) | $477.05M | $190.00K | $-374.16M | $103.08M | (m) | 3 month · $3.70M | (m) | (m) |
| 2019-09-30 | (m) | $470.43M | $181.00K | $-318.52M | $152.08M | (m) | 12 month · $11.17M | 12 month · $0.00 | (m) |
| 2019-06-30 | (m) | $463.23M | $117.00K | $-287.34M | $176.00M | (m) | 3 month · $3.03M 9 month · $7.81M | (m) | (m) |
| 2019-03-31 | $0.00 | $375.04M | $-136.00K | $-259.43M | $115.48M | (m) | 3 month · $2.91M 6 month · $4.78M | (m) | (m) |
| 2018-12-31 | $0.00 | $372.07M | $24.00K | $-233.49M | $138.60M | (m) | 3 month · $1.86M | (m) | (m) |
| 2018-09-30 | $0.00 | $9.35M | $87.00K | $-210.85M | $-201.42M | (m) | 12 month · $2.96M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-182.76M | (m) | 3 month · $603.00K 9 month · $1.88M | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-165.72M | (m) | 3 month · $736.00K 6 month · $1.27M | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $-149.70M | (m) | 3 month · $536.00K | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | $-133.36M | (m) | 12 month · $1.89M | 12 month · $4.00K | 12 month · $486.00K |
| 2016-09-30 | (m) | (m) | (m) | (m) | $-76.61M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |